Abstract：
UNASSIGNED: Gastroparesis that is refractory to standard dietary and medical management may benefit from surgical treatment with gastric electrical neurostimulation, which has shown promise in reducing symptoms of the disease. Pyloroplasty may serve an adjunctive role to a gastric stimulator, but the precise benefit remains unclear. The present study compares reported rates of symptom improvement following gastric neurostimulator implantation with and without pyloroplasty.
UNASSIGNED: A single center retrospective analysis of consecutive patients who received operative management for symptom refractory gastroparesis from 1 January 2020 to 31 December 2021 was performed. Subjects were assigned to cohorts based on treatment with gastric electrical stimulation alone (GES-only) or combined with pyloroplasty (GES + PP). A survey-based assessment was administered post-operatively that evaluated cardinal symptoms of gastroparesis (nausea, vomiting, early satiety) before and after treatment.
UNASSIGNED: In total, 42 patients (15 GES-only, 27 GES + PP) were included in the study. Both groups reported a high degree of improvement in global symptom control following surgery (93% vs 81%) with no differences between treatment cohorts (p = 0.09). Early satiety demonstrated better improvement in patients who received gastric stimulation alone (p = 0.012). Subgroup analysis of diabetic gastroparesis patients showed a 2.2% decrease in hemoglobin A1c levels in the GES + PP group (p-0.034).
UNASSIGNED: Symptom reduction in refractory gastroparesis appears to improve after placement of a gastric neurostimulator with or without the addition of a pyloroplasty procedure.
UNASSIGNED: A single center retrospective analysis of consecutive patients who received operative management for symptom refractory gastroparesis from 1 January 2020 to 31 December 2021 was performed. Subjects were assigned to cohorts based on treatment with gastric electrical stimulation alone (GES-only) or combined with pyloroplasty (GES + PP). A survey-based assessment was administered post-operatively that evaluated cardinal symptoms of gastroparesis (nausea, vomiting, early satiety) before and after treatment.
UNASSIGNED: In total, 42 patients (15 GES-only, 27 GES + PP) were included in the study. Both groups reported a high degree of improvement in global symptom control following surgery (93% vs 81%) with no differences between treatment cohorts (p = 0.09). Early satiety demonstrated better improvement in patients who received gastric stimulation alone (p = 0.012). Subgroup analysis of diabetic gastroparesis patients showed a 2.2% decrease in hemoglobin A1c levels in the GES + PP group (p-0.034).
UNASSIGNED: Symptom reduction in refractory gastroparesis appears to improve after placement of a gastric neurostimulator with or without the addition of a pyloroplasty procedure.
摘要：
■标准饮食和医疗管理难以治疗的胃轻瘫可能受益于胃电神经刺激的手术治疗，在减轻疾病症状方面显示出了希望。幽门成形术可能对胃刺激器起辅助作用，但确切的益处尚不清楚。本研究比较了有或没有幽门成形术的胃神经刺激器植入后症状改善的报告率。
■对2020年1月1日至2021年12月31日因症状难治性胃轻瘫接受手术治疗的连续患者进行单中心回顾性分析。基于单独使用胃电刺激(仅GES)或与幽门成形术(GES+PP)组合的治疗,将受试者分配到群组。术后进行了一项基于调查的评估，评估了胃轻瘫的主要症状（恶心，呕吐,早期饱腹感）治疗前后。
■总共，42例患者（15例仅GES，27GES+PP)纳入研究。两组均报告了手术后总体症状控制的高度改善（93％vs81％），治疗组之间没有差异（p=0.09）。仅接受胃刺激的患者的早期饱腹感得到了更好的改善（p=0.012）。糖尿病性胃轻瘫患者的亚组分析显示，GES+PP组的血红蛋白A1c水平下降2.2%(p-0.034)。
■难治性胃轻瘫的症状减轻在放置胃神经刺激器并添加或不添加幽门成形术后似乎有所改善。
■对2020年1月1日至2021年12月31日因症状难治性胃轻瘫接受手术治疗的连续患者进行单中心回顾性分析。基于单独使用胃电刺激(仅GES)或与幽门成形术(GES+PP)组合的治疗,将受试者分配到群组。术后进行了一项基于调查的评估，评估了胃轻瘫的主要症状（恶心，呕吐,早期饱腹感）治疗前后。
■总共，42例患者（15例仅GES，27GES+PP)纳入研究。两组均报告了手术后总体症状控制的高度改善（93％vs81％），治疗组之间没有差异（p=0.09）。仅接受胃刺激的患者的早期饱腹感得到了更好的改善（p=0.012）。糖尿病性胃轻瘫患者的亚组分析显示，GES+PP组的血红蛋白A1c水平下降2.2%(p-0.034)。
■难治性胃轻瘫的症状减轻在放置胃神经刺激器并添加或不添加幽门成形术后似乎有所改善。
